Efficacy and safety profiles of manidipine compared with amlodipine: A meta-analysis of head-to-head trials

Blood Pressure

Volumn 20, Issue 1, 2011, Pages 54-59

  Richy, Florent F ^a   Laurent, Stephane ^b  

^a Universite de Liege   (Belgium)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Ankle oedema; calcium antagonists; hypertension; meta analysis

Indexed keywords

AMLODIPINE; MANIDIPINE;

ANKLE EDEMA; ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; HUMAN; HYPERTENSION; META ANALYSIS; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AMLODIPINE; ANKLE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIHYDROPYRIDINES; EDEMA; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79251508391     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.518670     Document Type: Article

References (19)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;119: e1-e161.
2. Mancia G, de Backer G, Cifkova R, Dominiczak A, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH). J Hypertens. 2007;25:1105-1187.
3. Ezzati M, Lopez AD, Rodgers A, Vandeer Horn S, Murray CJL, and the Comparative Risk Assessment Collaborative Group. Lancet. 2002;360:1347-1360.
4. Coyne KS, Davis D, Frech F, Hill MN. Health-related quality of life in patients treated for hypertension: A review of the literature from 1990 to 2000. Clin Ther. 2002;24:142-169.
5. Bramlage P, Thoenes M, Kirch W, Lenfant C. Clinical prac-tice and recent recommendations in hypertension manage-ment-reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin. 2007;23: 783-791.
6. Opie LH. Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther. 1988;2:177-189.
7. Fogari R. Ankle oedema and sympathetic activation. Drugs. 2005;65 Suppl 2:21-7.
8. Coca Payeras A, Sladek K, Lembo G, Alberici M. Antihyper-tensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. Clin Drug Investig. 2007;27:623-632.
9. Martinez-Martin F, Rodriguez-Rosas H, Peiro-Martinez I et al. Relationship between sympathetic activation, pulse pres-sure and heart rate in hypertensive type 2 diabetic patients with microalbuminuria, treated with manidipine vs. amlo-dipine. J Hypertens. 2005;23:376.
10. Martinez-Martin F Manidipine in hypertensive patients with metabolic syndrome: The MARIMBA Study. Expert Rev Cardiovasc Ther. 2009;7:863-867
11. Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001;38:642-650.
12. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
13. Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119-1129.
14. Borenstein M, Hedges L, Higgins J, Rothstein H. Compre-hensive meta-analysis, Version 2. Englewood Cliffs, NJ: Biostat Inc.; 2005.
15. Simons LA, Ortiz M, Calcino G. Persistence with antihyper-tensive medication: Australia-wide experience. Med J Aust. 2008;188:224-227.
16. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP Discon-tinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. BMJ. 1995:311:293-295.
17. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihyperten-sive drugs. J Hypertens. 2005;23:2101-2107.
18. Fogari R, Zoppi A, Corradi L, Preti P, Malalamani GD, Mugellini A. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hyperten-sion. J Hypertens. 2000;18:1871-1875.
19. Fogari R, Malamani GD, Zoppi A, Mugellini A, Viscardi A, Lastoria C, et al. Manidipine has less oedematigeneous potential than amlodipine [abstract]. J Hypertens. 2000;18 Suppl 2:S154-155.